SGLT2 inhibitor use linked to reduced odds of all-cause dementia, psychiatric ED visits in intention-to-treat analysis.
Phase 2 Data Boosts Investor ConfidenceQ32 Bio Inc. (NASDAQ:QTTB) shares surged 60% on Monday after the biotechnology company ...
Q32 Bio (NASDAQ:QTTB) reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2a clinical trial ...
The latest phase 2 readout for Q32 Bio’s alopecia hopeful received a warm reception from investors, backing up the biotech’s ...
It is easy to forget just how terrible the Dred Scott decision was.
The UK Chancellor of the Exchequer has sent a formal letter to the Financial Conduct Authority laying out a set of ...
Harvey Weinstein’s trials highlight concerns about admitting prior acts as propensity evidence under New York law, which aims ...
Prime Video’s first images for Mike Flanagan’s Carrie series starring Summer H. Howell have ignited discussions on plus-size ...
When organizations reduce friction, focus on outcomes, and design around the employee experience, they create environments ...
Joseph J. Thorndike argues proposals to tax AI belong to the old habit in American politics of using the tax system to manage ...
Q32 Bio Inc. ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results